|
It is with considerable pride that I have seen Bioxel achieve milestones and set the stage for a promising future. Today, our Corporation is not only ready to begin reaping the benefits of its efforts to develop the international paclitaxel market, but is also solidly positioned to capitalize on the near-term opening up of the docetaxel market upon the gradual expiry of Sanofi-Aventis' patents to this molecule. In our eyes, these advances basically mean one thing: we are poised to see the vision underpinning Bioxel Pharma's founding some twelve years ago materialize. We have come a long way and overcome many obstacles since then. That is why a single option is open to us today: to redouble our efforts and to ultimately become a source of creation of shareholder value. I know many of you are impatient to achieve these objectives, and I urge all of you to imitate your Board members and to unreservedly support the hard, passionate and thoughtful work of every member of our team. Being so close to the goal without benefiting from a commensurate market valuation is a very under- standable source of frustration for our investors. We nevertheless remain confident that the market will sooner or later recognize the full potential of Bioxel Pharma. Pierre Lapalme
President and acting CEO Top  |
Stock information
| Symbol |
TSX : BIP |
| Last trade |
0.045 |
| Open |
0.035 |
| Net change |
+0.01 |
| High |
0.045 |
| Low |
0.035 |
| 52 week range |
0.04 - 0.25 |
| Volume |
24,500 |
| As of |
2008-11-21
13:32 EST |
Quotes are delayed. For informational purposes only.
|
